Valuation: Eli Lilly and Company

Market Cap 1,051B 19,319B 939B 873B 794B 1,500B 101,731B 1,506B 10,511B 4,118B 51,866B 3,947B 3,861B 166,440B P/E 2026 *
33.6x
P/E 2027 * 26x
Enterprise Value 1,077B 19,803B 962B 895B 814B 1,537B 104,281B 1,544B 10,774B 4,222B 53,166B 4,046B 3,958B 170,612B EV / Sales 2026 *
12.2x
EV / Sales 2027 * 10.3x
Free-Float
99.84%
Yield 2026 *
0.58%
Yield 2027 * 0.65%
1 day+6.44%
1 week+3.88%
Current month+3.28%
1 month+13.08%
3 months+4.59%
6 months+33.53%
Current year+11.53%
1 week 20,350
Extreme 20350
21,680
1 month 19,415.01
Extreme 19415.01
21,773
Current year 14,915
Extreme 14915
21,925.29
1 year 14,600
Extreme 14600
21,925.29
3 years 9,532.52
Extreme 9532.52
21,925.29
5 years 4,803
Extreme 4803
21,925.29
10 years 1,354.8
Extreme 1354.8
21,925.29
Manager TitleAgeSince
Chief Executive Officer 58 2016-12-31
Director of Finance/CFO 49 2024-09-08
Chief Tech/Sci/R&D Officer 52 -
Director TitleAgeSince
Director/Board Member 66 2004-12-31
Director/Board Member 70 2009-03-31
Director/Board Member 54 2011-12-11
Change 5-day change 1-year change 3-year change Capi.($)
+6.44%+3.88% - - 1,051B
+0.83%+3.19%+41.49%+103.56% 1,051B
+1.93%+2.11%+37.08%+65.09% 630B
+1.49%+5.19%+19.94%+85.69% 489B
+2.26%+0.90%+69.32%+40.53% 359B
+1.45%+3.50%+23.29%+41.62% 344B
+1.17%+2.37%+13.47%+33.64% 272B
+0.89%+1.08%-6.13%+9.29% 246B
+1.82%+2.94%+42.99%+52.95% 224B
+2.77%+4.44%+29.01%+98.99% 187B
Average +2.10%+2.53%+30.05%+59.04% 422.63B
Weighted average by Cap. +2.55%+2.44%+33.36%+69.01%

Financials

2026 *2027 *
Net sales 88.5B 1,627B 79.04B 73.53B 66.88B 126B 8,565B 127B 885B 347B 4,367B 332B 325B 14,013B 102B 1,881B 91.41B 85.04B 77.35B 146B 9,906B 147B 1,023B 401B 5,050B 384B 376B 16,207B
Net income 31.41B 577B 28.05B 26.09B 23.74B 44.81B 3,040B 45.01B 314B 123B 1,550B 118B 115B 4,973B 40.74B 749B 36.39B 33.85B 30.79B 58.13B 3,943B 58.38B 407B 160B 2,010B 153B 150B 6,451B
Net Debt 26.35B 484B 23.53B 21.89B 19.91B 37.59B 2,550B 37.76B 263B 103B 1,300B 98.94B 96.78B 4,172B 3.11B 57.12B 2.78B 2.58B 2.35B 4.43B 301B 4.45B 31.08B 12.18B 153B 11.67B 11.42B 492B
Projected Income Statement - Annual - Eli Lilly and Company
Logo Eli Lilly and Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (74%): products for treating osteoporosis, diabetes, and growth problems; - oncology (14.4%); - immunology diseases (8.1%); - neurology (2.1%): primarily drugs used in treating depression and schizophrenia; - other (1.4%). Net sales are distributed geographically as follows: the United States (66.7%), Europe (17.7%), Japan (3.2%), China (3%) and other (9.4%).
Employees
50,000
Date Price Change Volume
26-10-09 MX$21,659.98 +6.44% 161
26-10-08 MX$20,350.00 -5.16% 782
26-10-07 MX$21,458.00 +2.33% 145
26-10-06 MX$20,969.00 +1.28% 21
26-10-05 MX$20,705.01 -0.70% 55
Trader
Investor
Global
Quality
ESG MSCI
A
Ratings Surperformance© - Eli Lilly and Company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
1,179.27USD
Average target price
1,330.14USD
Spread / Average Target
+12.79%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Eli Lilly and Company